Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640523 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00640523 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT00640523, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Interventions
- DRUG forodesine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640523
The ClinicalTrials.gov registry entry for NCT00640523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which forodesine HCl is the first listed.
NCT00640523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640523 about?
NCT00640523 is a clinical study titled "Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)". To evaluate the effectiveness and safety of forodesine in CLL patients
What is the current status of trial NCT00640523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00640523?
The interventions under investigation include: forodesine HCl (DRUG).
Who is sponsoring clinical trial NCT00640523?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.